ArticleMicrobiology and immunology2025
Anti-Human Endogenous Retrovirus and Anti-Myelin Oligodendrocyte Glycoprotein Humoral Response in Cerebrospinal Fluid of Multiple Sclerosis Patients: A Case Control Study.
Article in Microbiology and immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
It is believed that human endogenous retrovirus (HERV)-W plays a fundamental role in multiple sclerosis (MS) pathogenesis, probably by inducing humoral and cellular immunopathological response. HERVs present regions of similarity to myelin oligodendrocyte glycoprotein (MOG) and therefore could induce autoimmunity through the mechanism of molecular mimicry via cross-humoral response. This study aimed to evaluate the impact of HERV-mediated humoral response among MS patients by assessing IgG antibody levels of HERV-W and K in cerebrospinal fluid (CSF). CSF samples were collected from MS patients (n = 25) and idiopathic intracranial hypertension (IIH) patients (n = 25). Serum samples from MS group (n = 25) were also analyzed. CSF samples were assessed for global and differential cell counts, analytical biochemistry, and oligoclonal bands analysis. ELISA was used to determine the serum and intrathecal (CSF) presence and concentration of anti-MOG, anti-HERV-W-env, and anti-HERV-K-pol antibodies. ELISA findings revealed higher concentrations of anti-MOG and HERV-W IgG in MS compared to IIH (p < 0.01 and p = 0.0142 respectively), while HERV-K IgG showed concentration to three HERV-K peptides (p < 0.01). A positive correlation was also observed between serum and CSF antibody concentration for MOG (r = 0.47 p = 0.01), HERV-W (r = 0.72 p < 0.01), and three HERV-K peptides (r = 0.49, 0.57, 0.61 and p = 0.0126, p < 0.01, and p < 0.01, respectively) among MS patients. Our findings revealed high concentrations of anti-HERV-K and -W antibodies in serum and CSF among MS patients, suggesting a possible role of humoral immunopathological response. In addition, the positive correlation between serum and CSF antibody concentration indicates the potential application of serum levels of anti-HERV and anti-MOG as biomarkers for MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.